JP2020506898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506898A5 JP2020506898A5 JP2019538383A JP2019538383A JP2020506898A5 JP 2020506898 A5 JP2020506898 A5 JP 2020506898A5 JP 2019538383 A JP2019538383 A JP 2019538383A JP 2019538383 A JP2019538383 A JP 2019538383A JP 2020506898 A5 JP2020506898 A5 JP 2020506898A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022168448A JP7585272B2 (ja) | 2017-01-17 | 2022-10-20 | 改善された血清アルブミン結合剤 |
| JP2024194438A JP2025024012A (ja) | 2017-01-17 | 2024-11-06 | 改善された血清アルブミン結合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446992P | 2017-01-17 | 2017-01-17 | |
| US62/446,992 | 2017-01-17 | ||
| PCT/EP2018/051082 WO2018134234A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168448A Division JP7585272B2 (ja) | 2017-01-17 | 2022-10-20 | 改善された血清アルブミン結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506898A JP2020506898A (ja) | 2020-03-05 |
| JP2020506898A5 true JP2020506898A5 (enExample) | 2021-01-07 |
| JP7300385B2 JP7300385B2 (ja) | 2023-06-29 |
Family
ID=61163666
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538383A Active JP7300385B2 (ja) | 2017-01-17 | 2018-01-17 | 改善された血清アルブミン結合剤 |
| JP2022168448A Active JP7585272B2 (ja) | 2017-01-17 | 2022-10-20 | 改善された血清アルブミン結合剤 |
| JP2024194438A Pending JP2025024012A (ja) | 2017-01-17 | 2024-11-06 | 改善された血清アルブミン結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168448A Active JP7585272B2 (ja) | 2017-01-17 | 2022-10-20 | 改善された血清アルブミン結合剤 |
| JP2024194438A Pending JP2025024012A (ja) | 2017-01-17 | 2024-11-06 | 改善された血清アルブミン結合剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11897944B2 (enExample) |
| EP (3) | EP4442708A3 (enExample) |
| JP (3) | JP7300385B2 (enExample) |
| KR (2) | KR20230165374A (enExample) |
| CN (2) | CN110461870B (enExample) |
| AU (2) | AU2018209150B2 (enExample) |
| BR (1) | BR112019014600A2 (enExample) |
| CA (1) | CA3050574A1 (enExample) |
| DK (1) | DK3571224T3 (enExample) |
| ES (1) | ES2994387T3 (enExample) |
| FI (1) | FI3571224T3 (enExample) |
| HR (1) | HRP20241501T1 (enExample) |
| HU (1) | HUE068820T2 (enExample) |
| IL (3) | IL305912B2 (enExample) |
| LT (1) | LT3571224T (enExample) |
| MX (4) | MX2019008536A (enExample) |
| PL (1) | PL3571224T3 (enExample) |
| PT (1) | PT3571224T (enExample) |
| RS (1) | RS66173B1 (enExample) |
| SG (2) | SG11201906341XA (enExample) |
| SI (1) | SI3571224T1 (enExample) |
| WO (1) | WO2018134234A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| IL310340A (en) * | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| KR102662499B1 (ko) * | 2017-01-17 | 2024-05-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| MX2019008536A (es) * | 2017-01-17 | 2019-09-10 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| MX2022006880A (es) | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23. |
| KR20220111313A (ko) | 2019-12-06 | 2022-08-09 | 아블린쓰 엔.브이. | TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| TWI861302B (zh) | 2019-12-09 | 2024-11-11 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| EP4126971A1 (en) | 2020-03-30 | 2023-02-08 | Ablynx N.V. | Method for the production and purification of multivalent immunoglobulin single variable domains |
| MX2023003522A (es) | 2020-09-25 | 2023-04-19 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l. |
| WO2022089435A1 (en) * | 2020-10-27 | 2022-05-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| PH12023500009A1 (en) | 2020-12-18 | 2024-03-11 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP4262985A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| TW202342508A (zh) | 2021-12-17 | 2023-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽 |
| CA3256757A1 (en) * | 2022-05-23 | 2023-11-30 | Cereius, Inc. | HER2 LIAISON AGENTS AND THEIR USES |
| TW202415678A (zh) | 2022-06-14 | 2024-04-16 | 比利時商艾伯霖克斯公司 | 靶向ｔ細胞受體的免疫球蛋白單可變結構域 |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| EP4665755A1 (en) | 2023-02-17 | 2025-12-24 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| AR134267A1 (es) | 2023-11-08 | 2025-12-17 | Sanofi Sa | Degradador lisosómico basado en cd25 y usos del mismo |
| TW202540188A (zh) | 2023-12-01 | 2025-10-16 | 比利時商艾伯霖克斯公司 | 精準活化的多肽 |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026052756A1 (en) | 2024-09-05 | 2026-03-12 | Ablynx Nv | Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| RU2464276C2 (ru) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| CN101454344A (zh) | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| AU2008252853B2 (en) | 2007-05-24 | 2011-12-01 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| LT2334705T (lt) * | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| KR20120092611A (ko) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| JP2013538566A (ja) | 2010-08-13 | 2013-10-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 改良された抗血清アルブミン結合変異体 |
| SG188204A1 (en) | 2010-08-20 | 2013-04-30 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012042026A1 (en) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PH12022550313A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3466972B1 (en) * | 2011-06-23 | 2026-03-04 | Ablynx NV | Serum albumin binding proteins |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| PH12014500380A1 (en) | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) * | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| AU2016209247B2 (en) | 2015-01-21 | 2021-02-25 | Inhibrx Biosciences, Inc. | Non-immunogenic single domain antibodies |
| ES2754427T3 (es) | 2015-05-13 | 2020-04-17 | Ablynx Nv | Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta |
| CA3003103A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| US11299751B2 (en) * | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| MX2019008536A (es) | 2017-01-17 | 2019-09-10 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR102662499B1 (ko) | 2017-01-17 | 2024-05-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
-
2018
- 2018-01-17 MX MX2019008536A patent/MX2019008536A/es unknown
- 2018-01-17 EP EP24191390.4A patent/EP4442708A3/en active Pending
- 2018-01-17 FI FIEP18703213.1T patent/FI3571224T3/fi active
- 2018-01-17 CN CN201880015687.2A patent/CN110461870B/zh active Active
- 2018-01-17 SI SI201831172T patent/SI3571224T1/sl unknown
- 2018-01-17 IL IL305912A patent/IL305912B2/en unknown
- 2018-01-17 BR BR112019014600-8A patent/BR112019014600A2/pt unknown
- 2018-01-17 JP JP2019538383A patent/JP7300385B2/ja active Active
- 2018-01-17 WO PCT/EP2018/051082 patent/WO2018134234A1/en not_active Ceased
- 2018-01-17 SG SG11201906341XA patent/SG11201906341XA/en unknown
- 2018-01-17 EP EP18703213.1A patent/EP3571224B1/en active Active
- 2018-01-17 HU HUE18703213A patent/HUE068820T2/hu unknown
- 2018-01-17 KR KR1020237040677A patent/KR20230165374A/ko not_active Ceased
- 2018-01-17 AU AU2018209150A patent/AU2018209150B2/en active Active
- 2018-01-17 DK DK18703213.1T patent/DK3571224T3/da active
- 2018-01-17 EP EP24191396.1A patent/EP4471058A3/en active Pending
- 2018-01-17 KR KR1020197024114A patent/KR102653724B1/ko active Active
- 2018-01-17 IL IL316293A patent/IL316293A/en unknown
- 2018-01-17 RS RS20241239A patent/RS66173B1/sr unknown
- 2018-01-17 IL IL267897A patent/IL267897B2/en unknown
- 2018-01-17 PT PT187032131T patent/PT3571224T/pt unknown
- 2018-01-17 HR HRP20241501TT patent/HRP20241501T1/hr unknown
- 2018-01-17 CA CA3050574A patent/CA3050574A1/en active Pending
- 2018-01-17 ES ES18703213T patent/ES2994387T3/es active Active
- 2018-01-17 SG SG10202108973SA patent/SG10202108973SA/en unknown
- 2018-01-17 CN CN202311114345.5A patent/CN117327175A/zh active Pending
- 2018-01-17 LT LTEPPCT/EP2018/051082T patent/LT3571224T/lt unknown
- 2018-01-17 PL PL18703213.1T patent/PL3571224T3/pl unknown
- 2018-01-17 US US16/477,927 patent/US11897944B2/en active Active
-
2019
- 2019-07-17 MX MX2024013316A patent/MX2024013316A/es unknown
- 2019-07-17 MX MX2024008521A patent/MX2024008521A/es unknown
- 2019-07-17 MX MX2025010630A patent/MX2025010630A/es unknown
-
2022
- 2022-10-20 JP JP2022168448A patent/JP7585272B2/ja active Active
-
2024
- 2024-01-04 US US18/404,145 patent/US20240294617A1/en active Pending
- 2024-11-06 JP JP2024194438A patent/JP2025024012A/ja active Pending
-
2025
- 2025-04-07 AU AU2025202453A patent/AU2025202453A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506898A5 (enExample) | ||
| JP2020515518A5 (enExample) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP7304375B2 (ja) | 血清アルブミンに結合するタンパク質 | |
| RU2022101604A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| IL316293A (en) | Improved serum albumin binders | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| JP2018537421A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| JPWO2020069028A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JPWO2022111425A5 (enExample) | ||
| JPWO2020229842A5 (enExample) | ||
| RU2023110757A (ru) | Усовершенствованные агенты, связывающие сывороточный альбумин | |
| RU2023102139A (ru) | Усовершенствованные связывающиеся с сывороточным альбумином вещества | |
| RU2019125831A (ru) | Усовершенствованные связывающиеся с сывороточным альбумином вещества | |
| RU2019118441A (ru) | Рекрутирующие т-клетки полипептиды, способные связывать cd123 и tcr альфа/бета |